NDA 050575 · US Antibiotics
Augmentin '125'
Amoxicillin, Clavulanate Potassium · Oral
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Aug 6, 1984
Approved uses
1
Original approval plus efficacy supplements
Registered trials
918
176 Phase 3, 89 recruiting
FAERS reports
27,162
21,127 serious, 2,624 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 26, 2026.
AUGMENTIN is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below: Lower Respiratory Tract Infections - caused by beta‑lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis . Acute Bacterial Otitis Media - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Sinusitis - caused by beta‑lactamase–producing isolates of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by beta‑lactamase–producing isolates of Staphylococcus aureus , Escherichia coli , and Klebsiella species. Urinary Tract Infections - caused by beta‑lactamase–producing isolates of E. coli , Klebsiella species, and Enterobacter species. AUGMENTIN is a combination of amoxicillin, a penicillin-class antibacterial and clavulanate potassium, a beta‑lactamase inhibitor indicated for treatment of the following infections in adults and pediatric patients: ( 1 ) Lower respiratory tract infections Acute bacterial otitis media Sinusitis Skin and skin structure infections Urinary tract infections Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, AUGMENTIN should not be used. ( 1 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN and other antibacterial drugs, AUGMENTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1 ) Limitations of Use When susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, AUGMENTIN should not be used. Usage To reduce the development of drug‑resistant...
Mechanism: AUGMENTIN is an antibacterial drug [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 6, 1984 Original approval · Type 3 - New Dosage Form
2 products under this application
- AUGMENTIN '125' · AMOXICILLIN 125MG/5ML; CLAVULANATE POTASSIUM EQ 31.25MG BASE/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
- AUGMENTIN '250' · AMOXICILLIN 250MG/5ML; CLAVULANATE POTASSIUM EQ 62.5MG BASE/5ML · FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Amoxicillin" as an intervention, any sponsor and status, largest first.
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06461429 · 100,000 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 31, 2050
Drug: Erythromycin; Amoxicillin and Erythromycin and 4 more · For: Preterm Birth
- Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer MortalityPivotal-lookingRecruiting
International Agency for Research on CancerAcademic, hospital or other
NCT02047994 · 30,000 participants (planned) · Start Mar 2013 · Primary completion Dec 2033
Drug: Triple therapy · For: Helicobacter Pylori Infections; Atrophic Gastritis; Gastric Cancer
Sites: Riga, Latvia
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTsPivotal-lookingCompleted
Mbarara University of Science and TechnologyAcademic, hospital or other
NCT00720811 · 6,456 participants · Start Oct 2009 · Primary completion Jan 2012
Drug: Artemether-lumefantrine combination; amoxycillin and 2 more · For: Malaria; Pneumonia
Sites: Saponé, Burkina Faso; Kassane, Ghana; Iganga, Uganda · 4 sites in all
- Community-based Helicobacter Pylori EradicationStatus unknown
National Taiwan University HospitalAcademic, hospital or other
NCT00155389 · 5,000 participants (planned) · Start Jan 2004 · Primary completion Dec 2015
Drug: Helicobacter pylori eradication · For: Helicobacter Pylori Infection
Sites: Taipei, Taiwan · 2 sites in all
- Helicobacter Pylori Eradication and Follow-upStatus unknown
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05061732 · 4,447 participants (planned) · Start Sep 30, 2021 · Primary completion Jun 30, 2026
Drug: Rabeprazole; Bismuth potassium citrate and 7 more · For: Helicobacter Pylori Infection
Sites: Shanghai, China
- A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe PneumoniaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT04041791 · 4,392 participants · Start Aug 19, 2019 · Primary completion Apr 5, 2024
Drug: Benzyl penicillin; Gentamicin Sulfate and 3 more · For: Pneumonia
Sites: Machakos, Kenya
- Community Case Management of the Severe Pneumonia With Oral Amoxicillin in Children 2-59 Months of AgePivotal-lookingCompleted
Aga Khan UniversityAcademic, hospital or other
NCT01192789 · 4,070 participants · Start Feb 2008 · Primary completion Mar 2010
Drug: Amoxicillin · For: Severe Pneumonia
Sites: Matiari, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea1,873
- drug hypersensitivity1,824
- nausea1,449
- dyspnoea1,421
- pyrexia1,395
- fatigue1,292
- pneumonia1,204
- vomiting1,173
- rash1,031
- pain991
- headache947
- acute kidney injury860
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 563 |
| 2005 | 450 |
| 2006 | 205 |
| 2007 | 142 |
| 2008 | 140 |
| 2009 | 716 |
| 2010 | 673 |
| 2011 | 869 |
| 2012 | 927 |
| 2013 | 1,030 |
| 2014 | 1,246 |
| 2015 | 1,602 |
| 2016 | 2,143 |
| 2017 | 1,954 |
| 2018 | 2,378 |
| 2019 | 2,414 |
| 2020 | 2,029 |
| 2021 | 1,337 |
| 2022 | 1,405 |
| 2023 | 1,423 |
| 2024 | 1,386 |
| 2025 | 1,228 |
| 2026 | 898 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis.
Hong TC, El-Omar EM, Kuo YT, et al. · Lancet Gastroenterol Hepatol 2024 · Meta-Analysis, Systematic Review
- Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
Ju KP, Kong QZ, Li YY, et al. · Helicobacter 2024 · Systematic Review, Meta-Analysis
- Sulopenem versus Amoxicillin/Clavulanate for the Treatment of Uncomplicated Urinary Tract Infection.
Puttagunta S, Aronin SI, Gupta J, et al. · NEJM Evid 2025 · Clinical Trial, Phase III, Comparative Study
- Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Zhou BG, Jiang X, Ding YB, et al. · Helicobacter 2024 · Comparative Study, Meta-Analysis
- Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Qian HS, Li WJ, Dang YN, et al. · Am J Gastroenterol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Identifying the Best Initial Oral Antibiotics for Adults with Community-Acquired Pneumonia: A Network Meta-Analysis.
Kurotschka PK, Bentivegna M, Hulme C, et al. · J Gen Intern Med 2024 · Systematic Review, Network Meta-Analysis
Sponsor: US Antibiotics · Also marketed as Augmentin '250'
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.